Literature DB >> 23143068

Infusion of Escherichia coli lipopolysaccharide toxin in rats produces an early and severe impairment of baroreflex function in absence of blood pressure changes.

Alberto Radaelli1, Paolo Castiglioni, Maria Grazia Cerrito, Caterina De Carlini, Francesco Soriano, Marco Di Rienzo, Maria Luisa Lavitrano, Giovanni Paolini, Giuseppe Mancia.   

Abstract

The assessment of baroreflex function since the first appearance of endotoxemia is important because the arterial baroreflex should exert a protective role during sepsis. Nevertheless, contrasting results were previously reported. This could be due to the hemodynamic instability characterizing this condition that may per se interfere with reflex cardiovascular adjustments. The aim of our study was therefore to study the baroreflex function (a) since the very beginning of infusion of Escherichia coli lipopolysaccharide (LPS) toxin and (b) in absence of the unloading effect produced by a decrease in blood pressure. Lipopolysaccharide was infused in 10 rats for 20 min at the infusion rate of 0.05 mg · kg · min. Blood pressure was continuously measured before, during, and after infusion, and the baroreflex function was evaluated analyzing spontaneous fluctuations of systolic blood pressure and pulse interval by the sequence and transfer-function techniques. Plasma concentrations of inflammatory (interleukin 6, tumor necrosis factor α) and anti-inflammatory (interleukin 10) cytokines were measured in other eight rats, similarly instrumented, four of which receiving the same LPS infusion. We found that blood pressure levels did not change with the infusion of LPS, whereas inflammatory cytokines increased significantly. The baroreflex sensitivity was significantly reduced 10 min after the beginning of LPS infusion, reached values about half those at baseline within 15 min after the start of infusion, and remained significantly low after the end of infusion. In conclusion, we documented that septic shock inducing LPS infusion is responsible for a very rapid impairment of the baroreflex function, independent from the level of blood pressure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23143068     DOI: 10.1097/SHK.0b013e3182767daf

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

Review 1.  The autonomic nervous system in septic shock and its role as a future therapeutic target: a narrative review.

Authors:  Marta Carrara; Manuela Ferrario; Bernardo Bollen Pinto; Antoine Herpain
Journal:  Ann Intensive Care       Date:  2021-05-17       Impact factor: 6.925

2.  The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems.

Authors:  Benjamin Vandendriessche; Elke Rogge; Vera Goossens; Peter Vandenabeele; Johannes-Peter Stasch; Peter Brouckaert; Anje Cauwels
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

3.  Impact of lipopolysaccharide-induced acute inflammation on baroreflex-controlled sympathetic arterial pressure regulation.

Authors:  Takeshi Tohyama; Keita Saku; Toru Kawada; Takuya Kishi; Keimei Yoshida; Takuya Nishikawa; Hiroshi Mannoji; Kazuhiro Kamada; Kenji Sunagawa; Hiroyuki Tsutsui
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

4.  Patterns of cardiovascular variability after long-term sino-aortic denervation in unanesthetized adult rats.

Authors:  Alberto Radaelli; Giuseppe Mancia; Caterina De Carlini; Francesco Soriano; Paolo Castiglioni
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

5.  A Whole-Body Mathematical Model of Sepsis Progression and Treatment Designed in the BioGears Physiology Engine.

Authors:  Matthew McDaniel; Jonathan M Keller; Steven White; Austin Baird
Journal:  Front Physiol       Date:  2019-10-18       Impact factor: 4.566

6.  Effect of ringers acetate in different doses on plasma volume in rat models of hypovolemia.

Authors:  Svajunas Statkevicius; Attila Frigyesi; Peter Bentzer
Journal:  Intensive Care Med Exp       Date:  2017-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.